INNMF Amplia Therapeutics Limited

Established in 2000 and headquartered in Melbourne, Australia, Amplia Therapeutics Limited is a pharmaceutical firm dedicated to the discovery and development of focal adhesion kinase (FAK) inhibitors. The company's...…

Established in 2000 and headquartered in Melbourne, Australia, Amplia Therapeutics Limited is a pharmaceutical firm dedicated to the discovery and development of focal adhesion kinase (FAK) inhibitors. The company's therapeutic endeavors are concentrated on oncology (cancer) and chronic fibrotic diseases. Its drug development pipeline includes AMP945, a FAK inhibitor that has successfully completed Phase I clinical trials and is being explored for its efficacy in treating pancreatic cancer, idiopathic pulmonary fibrosis, and a broader spectrum of cancerous and fibrotic conditions. Another compound, AMP886, is also under development for potential applications in cancer and fibrotic disorders. Amplia Therapeutics maintains a strategic collaboration with the Garvan Institute of Medical Research in Sydney, and the company adopted its current name in September 2018, having previously operated as Innate Immunotherapeutics Limited.